Interview: Avedro executives discuss FDA approval of cross-linking system

Ocular Surgery News: The ophthalmology community in the U.S. has been waiting for this approval for quite a while. Can you put this into perspective for ophthalmologists and discuss the importance of this particular approval? Rajesh K. Rajpal, MD: I think ophthalmologists across the U.S. and eye care providers in general have been anxiously awaiting the ability to perform cross-linking, or to be able to offer cross-linking is probably a better way to say it, to progressive keratoconus patients, and it is a dramatic event for all of us in the eye care industry, but also especially for patients. We hear from so many patients who are anxiously awaiting this, so I think it has been a huge event and it is a major opportunity for patients to get care for something that they have not been able to in the past.